Home › Crohn's Disease › Indiana
Crohn's Disease clinical trials in Indiana
13 studies for Crohn's Disease are looking for participants at sites in Indiana.
Cities in Indiana
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Indiana University Health University Hospital ( Site 5022), Indianapolis
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Oct 2, 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastroenterology Health Partners /ID# 284145, New Albany
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 2, 2026 · NCT07697456Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Indiana University Health University Hospital /ID# 278129, Indianapolis
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06548542A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- IU Health University Hospital, Indianapolis
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07196722A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Riley Hospital for Children, Indianapolis
RecruitingPhase 3
Ages 3 and older · All sexes · Updated Sep 25, 2026 · NCT06663332Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Indiana University Health University Hospital, Indianapolis
- Gastroenterology Health Partners, New Albany
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184944A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Indiana University Health Riley Hospital for Children /ID# 256454, Indianapolis
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Sep 23, 2026 · NCT05995353A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Riley Childrens Hospital, Indianapolis
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Aug 24, 2026 · NCT05509777Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Indiana University Health Riley Hospital for Children /ID# 262215, Indianapolis
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Jun 24, 2026 · NCT06332534Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Riley Hospital for Children at Indiana University Health, Indianapolis
RecruitingPhase 4
Ages 6 to 17 · All sexes · Updated May 27, 2026 · NCT05781152Precise Infliximab Exposure and Pharmacodynamic Control
- Riley Hospital for Children, Indianapolis
RecruitingPhase 2/3
Ages 6 to 22 · All sexes · Updated May 5, 2026 · NCT05660746From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.